The U.S. House was frozen stuck this morning after the new Republican majority splintered yesterday, the first day of the 118th Congress, over who should be the next House speaker.
Representatives cannot be sworn in and the House cannot begin
…
Category: Federal
President Biden on Dec. 29 signed a $1.7 trillion omnibus appropriations bill for fiscal year 2023 that gave the 340B drug pricing program a slight funding boost.
The U.S. Health Resources and Services Administration’s Office of Pharmacy Affairs will get
…
The U.S. Centers for Medicare & Medicaid Services starting Jan. 1, 2024, will require all 340B covered entities—hospital and grantee—to use claims modifiers to identify drugs as having been purchased through 340B when they bill for separately payable Medicare Part
…
Drug manufacturer Viatris will give 340B covered entities credits on requests for purchases of dozens of NDCs at higher than 340B ceiling price during the first 11 days of August, the company says in a notice on the U.S. Health
…
Private practice oncologists have paid for a study to model what would happened in 2023 if Medicare paid 340B hospitals for physician administered drugs based on a survey of those hospitals’ drug acquisition costs taken during the COVID pandemic’s darkest
…
U.S. House and Senate appropriations committees want federal healthcare officials to brief them by April “on actions taken to safeguard covered entities’ lawful access to discounted drugs” under the 340B program.
The directive to the Health Resources and Services Administration
…
Biopharmaceutical manufacturer Amgen yesterday became the 10th drug manufacturer to sue the federal government over the government’s position that the 340B statute requires drug companies to provide 340B-priced drugs to multiple contract pharmacies without conditions.
California-based Amgen filed suit
…
Drug manufacturer Merck is providing refunds for charges above 340B ceiling prices on 23 NDCs purchased during Q4 2019, Q3 2021, and Q2 2022.
The U.S. Health Resources and Services Administration posted Merck’s Nov. 21 notice about the repayments on
…
As we reported on deadline on Tuesday, a federal district court ruled this week that Arkansas’ novel 340B antidiscrimination law is not preempted by federal laws governing the 340B program, a decision that strikes down one of two legal arguments
…
The 117th Congress appears destined to end without further action on the 340B program.
The House and Senate are on track to finish all work for the year by no later than Friday, Dec. 23. According to news reports yesterday,
…